Comparative Pharmacology
Head-to-head clinical analysis: ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE versus GLYCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE versus GLYCORT.
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE vs GLYCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albuterol is a beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle. Ipratropium bromide is an anticholinergic agent that inhibits muscarinic receptors, reducing bronchoconstriction and mucus secretion.
Glucocorticoid receptor agonist; modulates gene expression to produce anti-inflammatory and immunosuppressive effects.
Two inhalations (albuterol 90 mcg and ipratropium 18 mcg per inhalation) four times daily via oral inhalation. Maximum: 12 inhalations per day.
Intravenous: 2 mg/kg every 12 hours; Oral: 20 mg twice daily.
None Documented
None Documented
Albuterol: 3-6 hours (terminal half-life), prolonged in hepatic or renal impairment. Ipratropium: 1.5-2 hours (terminal half-life), clinical effects persist longer due to receptor binding.
3.5 hours (terminal); prolonged in hepatic impairment (up to 8 hours) and severe renal impairment (up to 6 hours)
Albuterol: 60-70% renal as unchanged drug and metabolites (primarily sulfate conjugate), 10-20% fecal. Ipratropium: 50-60% fecal (unabsorbed), 30-40% renal (metabolites); minimal renal excretion of unchanged drug.
Renal: 70% as unchanged drug; biliary/fecal: 25% (metabolites); 5% other
Category A/B
Category C
Anticholinergic
Anticholinergic